BioSpace News Archive

4Moving Biotech announces that it has enrolled its first patient for phase I of LASARE clinical trial study.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the successful completion of a new production line for the medical radioisotope non-carrier-added lutetium-177 at its production facility IAZ in Garching near Munich.

A new whitepaper, released by the Wyss Center for Bio and Neuroengineering, reveals the first neural signals recorded by the ABILITY brain-computer interface system.

BioAge Labs, Inc. announced that it will present updates on its NLRP3 inhibitor program at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany.

Castle Biosciences, Inc. today announced new data from a randomized controlled trial (RCT) showing that use of TissueCypher® Barrett’s Esophagus Test results can significantly improve a physician’s accuracy in assessing the risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in patients diagnosed with Barrett’s esophagus (BE), as well as adherence to guideline-recommended patient management strategies.

Can-Fite BioPharma Ltd. announced today the Company’s CEO Dr. Pnina Fishman will present its liver drug candidate, Namodenoson, at the H.C. Wainwright 6th Annual Conference.

Abiomed, Inc . (NASDAQ: ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023.

Theratechnologies Inc. today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August 31, 2022. All figures are in U.S. dollars unless otherwise stated.

Otonomy, Inc. today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests.

Provention Bio, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022, before the opening of the U.S. financial markets.